Impact on Market and Business Strategy

We discuss how China’s livestream industry enables brands to connect with Chinese consumers in an engaging and interactive manner and relevant marketplace regulations. E-commerce giant Alibaba’s Taobao Live has top market share in this industry,  followed by Douyin, Kuaishou, JD.com, and Baidu.


China’s livestream industry has witnessed exponential growth in recent years. This medium offers brands a unique opportunity to connect with Chinese consumers in an engaging and interactive manner.

In 2022, the total revenue of China’s e-commerce livestream sector is projected to reach RMB 1.2 trillion (US$180 billion) with total of 660 million viewers. This figure is expected to further grow to RMB 4.9 trillion (US$720 billion) in 2023, according to a 2021 iResearch report. This will account for 11.7 percent of total e-commerce sales in the country, injecting new impetus into the economy.

Livestream functions as a key means for brands to boost sales and for smaller operators, such as farmers, to have better access to consumers. It grew exponentially during the pandemic, which promoted people to shop online and gain interactive and immersive experiences amid lockdowns. Currently, the e-commerce giant Alibaba’s Taobao Live has taken the lion’s share of livestream, taking up 68.5 percent of consumers, followed by Douyin and Kuaishou. Other major Chinese internet players like JD.com and Baidu are also trying to grow their presence in the market.

In this article, we explore how livestream can generate profits and what are the effective ways to enter this massive market.

What is livestream and why is it popular?

The typical livestream session, enabled by mobile devices, features hosts promoting and selling goods while customers watch, chat with others, and shop, all at the same time. Livestream allows hosts to answer call-in questions from audiences in real time, which significantly enhances shopping experiences and attracts

Read More

3 Keys to Implementing Artificial Intelligence in Drug Discovery

AI-primarily based systems are significantly staying utilised for things these kinds of as virtual screening, physics-dependent organic activity assessment, and drug crystal-structure prediction.

Despite the buzz all around synthetic intelligence (AI), most business insiders know that the use of equipment discovering (ML) in drug discovery is nothing at all new. For additional than a ten years, scientists have employed computational techniques for quite a few functions, such as finding hits, modeling drug-protein interactions, and predicting reaction charges.

What is new is the hoopla. As AI has taken off in other industries, plenty of commence-ups have emerged promising to renovate drug discovery and design with AI-primarily based systems for things such as virtual screening, physics-based mostly organic action assessment, and drug crystal-construction prediction.

Buyers have built enormous bets that these commence-ups will be successful. Investment decision reached $13.8 billion in 2020 and additional than a single-3rd of substantial-pharma executives report using AI technologies.

Even though a couple of “AI-native” candidates are in clinical trials, all around 90% remain in discovery or preclinical progress, so it will get decades to see if the bets pay off.

Artificial Anticipations

Together with large investments arrives large expectations—drug the undruggable, dramatically shorten timelines, almost get rid of moist lab operate. Insider Intelligence projects that discovery prices could be lessened by as significantly as 70% with AI.

However, it is just not that straightforward. The complexity of human biology precludes AI from getting to be a magic bullet. On leading of this, info should be abundant and thoroughly clean sufficient to use.

Models ought to be trusted, future compounds have to have to be synthesizable, and medication have to go real-everyday living protection and efficacy exams. While this harsh actuality hasn’t slowed financial commitment, it has led to less corporations receiving funding, to devaluations, and to

Read More